Objectives: Endometrial cytology offers a reliable alternative to biopsy in endometrial cancer detection and it may be useful in obtaining material to study prognostic and predictive markers. Over the years, new sampling devices have been developed. Molecular alterations in endometrial cancers were previously described using formalin-fixed paraffin-embedded tissues with particular attention, in endometrioid carcinomas, to the PTEN-PI3K pathway. PTEN evaluation could be useful in endometrial carcinomas for selecting patients for target therapies. Study Design: We studied 51 endometrial samples collected using the Endogyn device and 71 obtained with the Endoflower dispositive device, and processed using liquid-based cytology. Most of the cases were matched with a corresponding histological biopsy. The overall accuracy of Endoflower was 100%. Immunohistochemistry (IHC) and immunocytochemistry (ICC) for PTEN were performed using monoclonal antibody 6H2.1 from DAKO. Results: The IHC showed PTEN-null glands in 4 cases. The same cancers were negative in ICC. Among the 10 carcinomas on cytology, PTEN-null glands were found in 1 case. All the normal endometrium control cases were positive in cytology and histology. Conclusions: Our results suggest that endometrial devices provide useful material for the diagnosis and evaluation of PTEN expression.

Keywords:
Liquid-based cytology, PTEN, Immunocytochemistry, Endometrial sampling device
1.
Plataniotis G, Castiglione M: Endometrial cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010;21(suppl 5):v41-v45.
2.
Llobet D, Pallares J, Yeramian A, et al: Molecular pathology of endometrial carcinoma: practical aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 2009;62:777-785.
3.
Hecht JL, Mutter GL: Molecular and pathologic aspects of endometrial carcinogenesis. J Clin Oncol 2006;24:4783-4791.
4.
Bansal N, Yendluri V: The molecular biology of endometrial cancers and the implications for pathogenesis, classification and targeted-therapy. Cancer Control 2009;16:8-13.
5.
Yin Y, Shen WH: PTEN: a new guardian of the genome. Oncogene 2008;27:5443-5453.
6.
Yuan R, Kay A, Berg WJ, Lebwohl D: Targeting tumorigenesis: development and use of mTOR inhibitors in cancer therapy. J Hematol Oncol 2009;27:45-57.
7.
Oza AM, Elit L, Tsao MS, Kamel-Reid S, Biagi J, et al: Phase II study of temsirolimus in women with recurrent or metastatic endometrial cancer: a trial of the NCIC Clinical Trials Group. J Clin Oncol 2011;29:3278-3285.
8.
Shoji K, Oda K, Kashiyama T, Ikeda Y, Nakagawa S, et al: Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas. PloS One 2012;7:e37431.
9.
Janku F, Wheler JJ, Westin SN, Moulder SL, Naing A, et al: PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations. J Clin Oncol 2012;30:777-782.
10.
Lacey JV, Mutter GL, Ronnett BM, Ioffe OB, Duggan MA, et al: PTEN expression in endometrial biopsies as a marker of progression to endometrial carcinoma. Cancer Res 2008;68:6014-6020.
11.
Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ, Ellenson LH: PIK3CA and PTEN mutations in uterine endometroid carcinoma and complex atypical hyperplasia. Clin Cancer Res 2006;15:5932-5935.
12.
Papaefthimiou M, Symiakaki H, et al: The role of liquid-based cytology associated with curettage in the investigation of endometrial lesions from postmenopausal women. Cytopathology 2005;16:32-39.
13.
Di Lorito A, Schmitt FC: (Cyto)pathology and sequencing: next (or last) generation? Diagn Cytopathol 2011;40:459-461.
14.
Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ: Histologic Typing of Female Genital Tract Tumors (International Histological Classification of Tumors), ed 2. New York, Springer, 1994, pp 1-189.
15.
Pallares J, Bussaglia E, Martinez-Guitarte JL, Dolcet X, Llobet D, et al: Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 2005;18:719-727.
16.
Norimatsu Y, Miyamoto M, Kobayashi TK, Moriva T, Shimizu K, et al: Diagnostic utility of phosphatase and tensin homolog, β-catenin and p53 for endometrial carcinoma by thin-layer preparations. Cancer 2008;114:55-64.
17.
Kipp BR, Medeiros F, Campion MB, et al: Direct uterine sampling with the Tao Brush sampler using a liquid-based preparation method for the detection of endometrial cancer and atypical hyperplasia. Cancer 2008;114:228-235.
18.
Kondo E, Tabata T, Koduka Y, et al: What is the best method of detecting endometrial cancer outpatients? - Endometrial sampling, suction curettage, endometrial cytology. Cytopathology 2008;19:28-33.
19.
Di Lorito A, Rosini S, Falò E, Gustapane S, Gomes M, et al: Molecular alterations in endometrial archived liquid-based cytology. Diagn Cytopathology 2013;41:492-496.
20.
Schmitt FC, Longatto-Filho A, Valent A, Vielh P: Molecular techniques in cytopathology practice. J Clin Pathol 2008;61:258-267.
21.
Athanassiadou P, Athanassiades P, Grapsa D, Grapsa D, Gonidi M, et al: The prognostic value of PTEN, p53 and β-catenin in endometrial carcinoma: a prospective immunocytochemical study. Int J Ginecol Cancer 2007;17:697-704.
22.
Djordjevic B, Hennessy BT, Barkoh BA, Luthra R, Mills GB, Broaddus RR: Clinical assessment of PTEN loss in endometrial carcinoma: immunohistochemistry outperforms gene sequencing. Mod Pathol 2012;25:699-708.
23.
Mutter GL, Lin MC, Fitzgerald JT: Alterated PTEN expression as a diagnostic marker for the earliest endometrial precancers. J Natl Cancer Inst 2000;92:924-930.
24.
O' Hara AJ, Bell DW: The genomics and genetics of endometrial cancer. Adv Genomics Genet 2012;2:33-47.
25.
Suh DH, Kim JW, Kim K, Kim HJ, Lee KH: Major clinical research advances in gynecologic cancer in 2012. J Gynecologic Oncol 2013;24:66-82.
26.
Forster MD, Dedes KJ, Sandhu S, Frentzas S, Kristeleit R, et al: Treatment with olaparib in a patient with PTEN-deficient endometrioid endometrial cancer. Nat Rev Clin Oncol 2011;8:302-306.
27.
Alvarez EZ, Brandy WE, Walker JL, Rotmensch J, Zhou XC, et al: Phase II trial of combination bevacizumab and temsirolimus in the treatment of recurrent or persistent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 2013;129:22-27.
28.
Kollmannsberger C, Hirte H, Siu LL, Mazurka J, Chi K, et al: Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179). Ann Oncol 2012;23:238-244.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.